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Abstract
Introduction:We sought to examine the association of race/ethnicity with willingness
to engage in studies that involve procedures typical of Alzheimer’s disease (AD) clinical
trials and determine whether any observed differences could be explained by research
attitudes.
Methods:We studied 2749 adults aged ≥50 years who enrolled in a community-based
recruitment registry.
Results: Compared to non-Hispanic (NH) whites (n = 2393, 87%), Hispanics (n = 191,
7%), NH Asians (n = 129, 5%) and NH blacks (n = 36, 1%) were 44%, 46%, and 64% less
willing, respectively, to be contacted for studies that have requirements typical of AD
prevention trials, namely: cognitive testing, brain imaging, blood draws, and investiga-
tional medications. Mediation by research attitudes was explored, but did not explain
the observed differences.
Discussion: Our findings suggest that ethnoracial minorities are less willing to engage
in studies that are typical of AD prevention trials. Future work should focus on under-
standing the factors that drive these differences.
K EYWORD S
Alzheimer’s disease, biomarker testing, prevention trials, race/ethnicity, recruitment, research
attitudes, research participation
1 BACKGROUND
In the United States, ethnoracial minorities bear a disproportionate
burden of Alzheimer’s disease (AD) and related dementias.1-3 Yet,
they remain severely underrepresented in dementia studies,4 par-
ticularly clinical trials.5,6 Greater participation of minority groups is
imperative because it leads to better generalization of trial findings
and could enable identification of potential differences in treatment
response between groups.7,8 In addition to testing experimental
medications, AD trials typically require participants to engage in
potentially burdensome procedures. Recruitment challenges may
worsen in the coming years asmore AD trials focus on enrolling prede-
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
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mentia populations, for whom sensitivities toward study risks may be
heightened.9
Online recruitment registries have emerged around the globe as a
novel approach for accelerating enrollment of participants in clinical
studies, including dementia research.10 Eligible individuals are iden-
tified from the community through various outreach modalities and
enrolled in a registry online. Researchers benefit by having access to
a large research-ready and often prescreened population. It remains
unclear whether registries can improve enrollment of ethnically and
racially diverse samples.
Some previous studies suggest that ethnoracial minorities are as
willing as their non-Hispanic (NH) white counterparts to participate
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in health research,11,12 while others report a lower willingness among
ethnoracial minorities.13-15 Negative attitudes toward research, such
as mistrust of clinical researchers, have been shown to be impor-
tant predictors for lower willingness to participate in clinical research
studies,16 including in AD trials.17
Improving our understanding of recruitment disparities by
race/ethnicity is of paramount importance for generalizability of
safety and efficacy of AD trials and is consistent with the goals set
forth by the National Institute on Aging’s National Strategy for Clinical
Research Recruitment.18 Accordingly, the present study leverages
data from a local online recruitment registry in southern California to
interrogate the relationship between race/ethnicity and older adults’
willingness to engage in research studies, and to explore whether this
potential association is mediated by research attitudes.
2 METHODS
2.1 Study population
The Consent-to-Contact (C2C) Registry was developed and launched
in August 2016 to accelerate enrollment of participants in clinical
research studies at the University of California, Irvine (UCI), with a
particular emphasis on preclinical AD trials.19 C2C participants were
aged 18 years and older and recruited from Orange County, CA dur-
ing 2016–2019 through enrollment strategies including earnedmedia,
community outreach activities, postcard mailings, e-mail, and social
media. Upon enrolling through the registry website, participants pro-
vided informed consent electronically and completed structured ques-
tionnaires that ascertained information about research willingness,
research attitudes, and sociodemographic and clinical characteristics.
For the current study, we restricted analyses to participants who were
aged50years or older. The Institutional ReviewBoard atUCI approved
this study.
2.2 Assessment of researchwillingness
The primary outcome was research willingness, which was assessed
using separate items that asked participants about their willingness to
be contacted for research studies that involved nine procedure types,
namely: (1) modification of diet or physical activity, (2) cognitive test-
ing, (3) blood draws, (4)magnetic resonance imaging (MRI), (5) positron
emission tomography (PET) imaging, (6) approved and (7) investiga-
tional medications, (8) lumbar puncture (LP), and (9) autopsy. For anal-
ysis, we excluded any participant who failed to respond to at least one
of these nine question items (n= 1).
2.3 Sociodemographic and clinical measures
Sociodemographic characteristics included self-reported
race/ethnicity, age, sex, and years of education. For our predictor
HIGHLIGHTS
• Ethnoracial minorities are underrepresented in
Alzheimer’s disease (AD) clinical trials.
• We studied 2749 adults aged≥50 years enrolled in a local
online recruitment registry.
• Willingness to be contacted for participation in AD trials
was lower inminorities.
• Research attitudes did not explain differences in willing-
ness by race/ethnicity.
RESEARCH INCONTEXT
1. Systematic Review: Numerous studies have reported
severe disparities in the recruitment of ethnoracial
minorities to clinical trials of Alzheimer’s disease (AD).
Less is known, however, about whether underrepre-
sentedminorities arewilling to engage in procedures typ-
ically done in AD trials.
2. Interpretation: We found that, in a community-based
recruitment registry, ethnoracial minorities were less
willing than non-Hispanic whites to engage in studies
involving cognitive testing, brain imaging, blood draws,
and investigational medications. These differences were
not explained by research attitudes.
3. Future Directions: Future work should focus on under-
standing the sociocultural and ethnicity-specific factors
that could potentially drive these differences.
of interest, we classified participants into four mutually exclusive
ethnoracial categories of NHwhite, NHAsian, NH black, andHispanics
of any race. Due to small numbers, we excluded participants who
self-identified as American Indian or Alaskan Native (n= 3) and Native
Hawaiian or other Pacific Islander (n= 2).We also excluded individuals
who self-identified with another race not specified (n = 36) and NH
participants who were of multiple racial backgrounds (n = 17). Sensi-
tivity analysis demonstrated that classifying multiracial participants
into a single (majority) race or excluding them altogether did not
change our findings. The final analytic sample was comprised of 2749
older adults.
We collected information about clinical characteristics from all par-
ticipants and included self-reported current medical conditions such
as cancer, diabetes, coronary artery disease, congestive heart failure,
kidney disease, liver disease, hypertension, hypercholesterolemia, and
emphysema. In analysis, the number of current medical conditions or
co-morbidities were grouped into three categories (none, 1, and ≥2).
We inquired about neurological diseases using the question, “Have you
ever been diagnosed with a neurological disorder?” and offering 13
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forced choice responses, including “other neurological disorder.” Sub-
jective cognitive function was assessed using the 14-item Cognitive
Function Inventory (CFI).20 Last, we collected information on the num-
ber of current prescription medications, which we grouped into four
categories (none, 1–2, 3–4, and≥5).
2.4 Assessment of research attitudes
Research attitudes, assessed using the 7-itemResearchAttitudeQues-
tionnaire (RAQ) with 5-point Likert-type responses,21 was a pri-
ori considered a potential mediator in the hypothesized relationship
between ethnoracial status and research willingness. Among those
who responded to at least six out of seven items, we operationalized
the construct of research attitudes into a summary score that ranged
from 7 to 35, with higher scores representing more positive research
attitudes.
2.5 Statistical analysis
To investigate the association between race/ethnicity and research
willingness, we fit separate logistic regression models for each of the
nine procedure types. Each model controlled for potential confound-
ing factors, which we identified a priori as age, sex, education, num-
ber of co-morbidities, number of concomitant medications, and CFI
scores. Estimated odds ratios (ORs) along with corresponding Wald-
based 95% confidence intervals were reported for the predictor of
interest in all models. In secondary analyses, we assessed for poten-
tialmediationof eachassociation22 by first quantifying the relationship
between: (1) race/ethnicity and research willingness, (2) race/ethnicity
and research attitudes, and (3) research attitudes and research will-
ingness adjusting for race/ethnicity. Next, we quantified the degree
of attenuation of the association between race/ethnicity and research
willingnesswhen research attitudes (operationalized as RAQ summary
score) was in the regression model. In sensitivity analysis, we assessed
TABLE 1 Distribution of characteristics among C2C participants aged≥50 years by race/ethnicity
Overall sample NHwhite Hispanic (any race) NHAsian NH black
Total N 2,749 2,393 (87.1%) 191 (7.0%) 129 (4.7%) 36 (1.3%)
Age, mean (SD) 66.1 (9.2) 66.7 (9.3) 61.1 (7.7) 64.4 (8.5) 62.8 (9.9)
Female sex, n (%) 1,694 (61.6%) 1,480 (61.9%) 117 (61.3%) 74 (57.4%) 23 (63.9%)
Educational attainment, n (%)
Less than high school (<12 years) 27 (1.0%) 18 (0.8%) 8 (4.3%) 1 (0.8%) 0
High school (12 years) 181 (6.7%) 143 (6.0%) 30 (16.0%) 5 (4.0%) 3 (8.3%)
Some college (13-15 years) 525 (19.3%) 445 (18.8%) 51 (27.3%) 16 (12.7%) 13 (36.1%)
College or higher (≥16 years) 1,983 (73.0%) 1,761 (74.4%) 98 (52.4%) 104 (82.5%) 20 (55.6%)
Sources of enrollment
Email outreach 1410 (51.8%) 1254 (53.0%) 86 (45.0%) 50 (39.4%) 20 (55.6%)
Community talks 281 (10.3%) 241 (10.2%) 17 (8.9%) 21 (16.5%) 2 (5.6%)
Postcardmailings 231 (8.5%) 192 (8.1%) 22 (11.5%) 14 (11.0%) 3 (8.3%)
Other
a
798 (29.3%) 679 (28.7%) 66 (34.6%) 42 (33.1%) 11 (30.6%)
No. of current co-morbidities
a
None 942 (34.3%) 798 (33.4%) 90 (47.1%) 43 (33.3%) 11 (30.6%)
1 895 (32.6%) 794 (33.2%) 41 (21.5%) 50 (38.8%) 10 (27.8%)
≥2 912 (33.2%) 801 (33.5%) 60 (31.4%) 36 (27.9%) 15 (41.7%)
Neurological disorder diagnosis (yes), n (%) 440 (16.2%) 401 (16.9%) 24 (12.8%) 12 (9.5%) 3 (8.6%)
No. of concomitant medications, n (%)
None 380 (14.4%) 309 (13.4%) 37 (20.4%) 27 (21.6%) 7 (21.9%)
1-2 753 (28.4%) 644 (27.9%) 58 (32.0%) 41 (32.8%) 10 (31.3%)
3-4 686 (25.9%) 614 (26.6%) 43 (23.8%) 24 (19.2%) 5 (15.6%)
≥5 830 (31.3%) 744 (32.2%) 43 (23.8%) 33 (26.4%) 10 (31.3%)
Cognitive Function Inventory scores, mean (SD) 2.8 (2.7) 2.7 (2.7) 3.4 (2.9) 3.4 (3.2) 2.9 (2.5)
Research attitude questionnaire scores, mean (SD) 28.7 (4.4) 28.7 (4.3) 28.4 (4.9) 28.6 (4.9) 27.9 (4.4)
Abbreviations: C2C, Consent-to-Contact; NH, non-Hispanic; SD, standard deviation
aOther sources include earnedmedia (newspaper [6.7%], television [<1%], radio [<1%]), social media (1.5%), online searches (3.6%), provider referral (4.0%),
friend referral (5.2%), and other sources not specified (7.5%).
aComorbidities include self-reported cancer, diabetes, coronary artery disease, congestive heart failure, kidney disease, liver disease, hypertension, hyperc-
holesterolemia, and emphysema.
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this degree of attenuation after adjustment for individual RAQ items
rather than the summarymeasure.
In exploratory analyses, we assessed the association between
race/ethnicity and research willingness in the context of AD pre-
vention by creating a composite measure to simulate the eligibility
requirements of an AD prevention trial.9 The measure grouped
five of the nine procedure types—namely (1) cognitive testing, (2)
MRI scans, (3) PET scans, (4) blood draws, and (5) investigational
medications—into a summary score that ranged from 0 to 5. Because
relatively few participants scored 0–2 (n = 120) on the composite
measure, we grouped these individuals together and created four
levels of scores. Additionally, we excluded 460 participants who had
a previous neurological disorder or non-basal cell cancers. We used
ordinal logistic regression to estimate cumulative ORs for having a
higher versus a lower score on the composite measure. Score tests on
eachmodel were used to test the null hypothesis that the proportional
odds assumption holds. In no case was there statistical evidence that
the proportionality assumption was violated.
We had a minimal amount of missing data in our outcome measure
of research willingness among those who responded to at least one
of the nine items; missing responses ranged from 0.8% to 1.2% across
items that had missing information. A total of 215 (7.8%) participants
had two or more missing RAQ items and were excluded from media-
tion analyses. Excluded participants were less likely to have a college
education (59% vs 74%, P< .0001), more likely to be using five ormore
concomitant medications (52% vs 31%, P < .0001), and more likely to
have two ormore co-morbidities (44% vs 32%, P= .0006). In ourmulti-
variable regression models, we used established methods for multiple
imputation,23 with20 imputeddata sets, to imputemissing information
on key adjustment variables of educational attainment (n = 33, 1.2%),
concomitant medications (n = 100, 3.6%), presence of a neurological
disorder (n = 29, 1.1%), and CFI scores (n = 332, 12.1%). We also used
TABLE 2 Distribution of research attitude responses by race/ethnicity
Level of agreement n (%)
Research AttitudeQuestionnaire itemsaa NHwhite Hispanic (any race) NHAsian NH black
1. I have a positive view aboutmedical research in
general.
Disagree 30 (1.4%) 3 (1.8%) 3 (2.5%) 0
Neutral 123 (5.6%) 16 (9.5%) 11 (9.1%) 5 (17.2%)
Agree 2,061 (93.1%) 149 (88.7%) 108 (88.5%) 24 (82.8%)
2. Medical researchers can be trusted to protect
the interests of people who take part in their
research studies
Disagree 38 (1.7%) 4 (2.4%) 4 (3.3%) 0
Neutral 374 (16.9%) 33 (19.5%) 22 (18.0%) 10 (34.5%)
Agree 1,799 (81.4%) 132 (78.1%) 96 (78.7%) 19 (65.5%)
3. We all have some responsibility to help others by
volunteering for medical research.
Disagree 783 (3.8%) 7 (4.1%) 4 (3.3%) 0
Neutral 414 (18.7%) 27 (16.0%) 19 (15.7%) 8 (27.6%)
Agree 1,716 (77.5%) 135 (79.9%) 98 (81.0%) 21 (72.4%)
4. Society needs to devotemore resources to
medical research.
Disagree 33 (1.5%) 6 (3.6%) 3 (2.5%) 0
Neutral 245 (11.1%) 16 (9.5%) 17 (14.0%) 3 (10.3%)
Agree 1,933 (87.4%) 147 (87.0%) 102 (83.6%) 26 (89.7%)
5. Participating inmedical research is generally safe. Disagree 55 (2.5%) 6 (3.6%) 5 (4.1%) 0
Neutral 518 (23.4%) 52 (31.1%) 29 (24.0%) 12 (41.4%)
Agree 1,637 (74.1%) 109 (65.3%) 87 (71.9%) 17 (58.6%)
6. If I volunteer for medical research, I knowmy
personal informationwill be kept private and
confidential.
Disagree 70 (3.2%) 5 (3.0%) 6 (4.9%) 0
Neutral 419 (19.0%) 29 (17.3%) 24 (19.7%) 11 (39.3%)
Agree 1,721 (77.9%) 134 (79.8%) 92 (75.4%) 17 (60.7%)
7. Medical research will find cures for manymajor
diseases duringmy lifetime.
Disagree 105 (4.8%) 9 (5.3%) 2 (1.7%) 2 (6.9%)
Neutral 467 (21.1%) 29 (17.2%) 31 (25.6%) 10 (34.5%)
Agree 1,640 (74.1%) 131 (77.5%) 88 (72.7%) 17 (58.6%)
Abbreviation: NH, non-Hispanic.
a5-point Likert-type responses were strongly disagree, disagree, neutral, agree, and strongly agree. We collapsed strongly agree with agree and strongly
disagree with disagree.
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a complete case approach and found that the results did not appre-
ciably change. No adjustment for multiple comparisons were used for
exploratory analyses. All statistical analyses were performed in SAS
version 9.4 (SAS institute Inc., Cary, NC).
3 RESULTS
The distribution of our study population characteristics is depicted in
Table 1. The sample was largely female (63%), had an average age of
66 years, and was highly educated (73% college or higher). Hispan-
ics tended to be younger and more likely to report no comorbidities
than NH whites (47% vs 33%). NH blacks were more likely than NH
whites to have≥2 co-morbidities (42%vs 34%) and less likely to be tak-
ing concomitant medications (78% vs 87%). Hispanics and NH Asians
had higher mean CFI scores than NHwhites. Notably, the overall aver-
age RAQ summary score was 29 and did not differ by race/ethnicity.
Roughly half of the sample enrolled through e-mail outreach, with NH
Asians more frequently having enrolled through community outreach.
Table 2 compares the distribution of responses for each of the RAQ
items across ethnoracial groups.Overall, roughly three quarters of par-
ticipants agreed with each item, and relatively few (<5%) disagreed.
Compared to NH whites, a higher proportion of NH blacks responded
“neutral” to RAQ items that inquired about having a positive view of
medical research (17% vs 6%), trust in medical researchers (35% vs
17%), viewing medical research as generally safe (41% vs 23%), confi-
dence that personal informationwouldbekept private and confidential
(39% vs19%), and confidence that medical research would find cures
to major diseases during their lifetimes (35% vs 21%). No appreciable
differences in responses were observed betweenNHwhites and other
ethnoracial groups.
Figure 1 shows the absolute differences in willingness to be con-
tacted for studies using various procedures by race/ethnicity. Across
each ethnoracial group, we observed that the proportion of partici-
pants who were willing to be contacted for studies was >70% for all
but two procedures—LP and autopsy—and >90% for studies involv-
ing diet/physical activity modification and cognitive testing. Fewer NH
blacks than NH whites were willing to be contacted for studies that
involved LP and autopsy (16% vs 42% and 47% vs 74%, respectively).
To further quantify these differences on a relative scale, Table 3
shows the association of race/ethnicity and willingness using logis-
tic regression models. Hispanics exhibited lower odds for willingness
relative to NH whites across all procedure types except for LP and
diet/physical activity modification (ORs ranged from 0.44 to 0.85,
unadjusted models). Adjustment for potential confounders (model 2)
strengthened associations in most cases, and only reached statistical
significance for studies involving PET scans and investigational medi-
cations (adjusted OR [aOR] = 0.56, 95% confidence interval [CI]: 0.36-
0.87 andaOR=0.61, 95%CI: 0.40-0.95, respectively). InNHAsians,we
similarly observed lower odds of willingness compared to NH whites
across amajority of procedure types, although the estimateswere gen-
erally larger in magnitude than those of Hispanics, and reached sta-
tistical significance for studies involving blood draws, investigational
medications, and autopsy in multivariable models. The one exception
was LP; NH Asians had 84% higher odds of willingness to be contacted
for studies involving LP than NH whites (aOR = 1.84, 95% CI: 1.28-
2.66). This association did not appreciably change after adjustment for
sources of enrollment (not shown). For NH blacks, we observed a simi-
lar pattern of lower odds forwillingness compared toNHwhites across
all but one procedure type, with the strongest associations observed
for studies that involved MRI, blood draws, LP, and autopsy (aORs
ranged from 0.26 to 0.31).
F IGURE 1 Percentage of participants by race/ethnicity willing to engage in studies of various research procedures
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TABLE 3 Association of race/ethnicity with willingness to be contacted for research studies
Odds ratios (95%CI) for willingness to be contacted
Type of procedure involved NHwhite Hispanic (any race) NHAsian NH black
Diet/physical activity modification Model 1a 1.00 (ref) 1.33 (0.67-2.65) 0.78 (0.40-1.52) 2.32 (0.32-17.0)
Model 2
b
1.00 (ref) 1.08 (0.53-2.21) 0.70 (0.35-1.38) 1.96 (0.26-14.5)
Model 3
c
1.00 (ref) 1.21 (0.54-2.67) 0.65 (0.33-1.29) 1.51 (0.20-11.4)
Cognitive testing Model 1a 1.00 (ref) 0.44 (0.20-0.94 0.60 (0.21-1.71) 0.68 (0.09-5.05)
Model 2
b
1.00 (ref) 0.52 (0.23-1.18) 0.55 (0.19-1.58) 0.74 (0.09-5.70)
Model 3
c
1.00 (ref) 0.50 (0.21-1.19) 0.51 (0.17-1.50) 0.62 (0.08-5.00)
MRI scans Model 1a 1.00 (ref) 0.74 (0.44-1.25) 1.49 (0.65-3.43) 0.30 (0.13-0.70)
Model 2
b
1.00 (ref) 0.68 (0.39-1.17) 1.37 (0.59-3.19) 0.29 (0.12-0.68)
Model 3
c
1.00 (ref) 0.67 (0.37-1.19) 1.26 (0.54-2.94) 0.32 (0.12-0.88)
PET scans Model 1a 1.00 (ref) 0.73 (0.50-1.05) 0.84 (0.53-1.33) 0.50 (0.24-1.05)
Model 2
b
1.00 (ref) 0.67 (0.46-0.98) 0.79 (0.50-1.26) 0.48 (0.22-1.01)
Model 3
c
1.00 (ref) 0.62 (0.42-0.93) 0.73 (0.45-1.17) 0.58 (0.24-1.40)
Blood draws Model 1a 1.00 (ref) 0.66 (0.38-1.16) 0.33 (0.19-0.55) 0.28 (0.12-0.69)
Model 2
b
1.00 (ref) 0.61 (0.34-1.10) 0.31 (0.18-0.53) 0.27 (0.11-0.68)
Model 3
c
1.00 (ref) 0.68 (0.36-1.29) 0.28 (0.16-0.49) 0.47 (0.14-1.60)
Approvedmedications Model 1a 1.00 (ref) 0.82 (0.52-1.28) 0.61 (0.38-0.99) 0.74 (0.28-1.91)
Model 2
b
1.00 (ref) 0.70 (0.43-1.12) 0.61 (0.37-1.02) 0.68 (0.25-1.81)
Model 3
c
1.00 (ref) 0.64 (0.39-1.05) 0.56 (0.33-0.94) 0.70 (0.23-2.12)
Investigational medications Model 1a 1.00 (ref) 0.74 (0.52-1.06) 0.58 (0.39-0.86) 0.58 (0.28-1.22)
Model 2
b
1.00 (ref) 0.62 (0.42-0.90) 0.54 (0.36-0.83) 0.52 (0.24-1.12)
Model 3
c
1.00 (ref) 0.58 (0.39-0.87) 0.49 (0.32-0.75) 0.43 (0.19-0.99)
Lumbar puncture Model 1a 1.00 (ref) 1.09 (0.81-1.46) 1.92 (1.34-2.76) 0.28 (0.12-0.67)
Model 2
b
1.00 (ref) 0.95 (0.70-1.30) 1.84 (1.28-2.66) 0.26 (0.11-0.63)
Model 3
c
1.00 (ref) 0.91 (0.66-1.27) 1.71 (1.17-2.49) 0.34 (0.13-0.85)
Autopsy Model 1a 1.00 (ref) 0.85 (0.61-1.17) 0.47 (0.32-0.70) 0.31 (0.16-0.61)
Model 2
b
1.00 (ref) 0.83 (0.59-1.16) 0.44 (0.30-0.63) 0.31 (0.16-0.59)
Model 3
c
1.00 (ref) 0.73 (0.51-1.04) 0.41 (0.28-0.60) 0.34 (0.16-0.72)
Abbreviations: CFI, Cognitive Function Inventory; CI, confidence interval; MRI, magnetic resonance imaging; NH, non-Hispanic; PET, positron emission
tomography; RAQ, Research AttitudeQuestionnaire
aModel 1 unadjusted.
bModel 2 adjusted for age, sex, educational attainment, number of comorbidities, neurological disorder diagnosis, number of medications and CFI scores.
cModel 3 further adjusted for RAQ scores.
When we considered potential mediation by research attitudes, we
observed no appreciable attenuation of the main effect estimates in
multivariable models that further adjusted for RAQ overall summary
scores (Table 3,model 3) orwhenweattempted to decompose the total
effect into the natural direct and indirect effects (not shown). Further-
more, we found no appreciable attenuation of the main effects in sen-
sitivity analyses that adjusted for individual RAQ items rather than an
overall RAQ summary score.
In exploratory analyses that grouped procedures according to
requirements typical of AD prevention trials, we observed 44%, 46%,
and 64% lower odds of willingness comparing Hispanics, NH Asians,
and NH blacks with NH whites, respectively (Table 4, adjusted model).
Other predictors for higher willingness in the multivariable model
included younger age, beingmale, and higher CFI and RAQ scores.
4 DISCUSSION
In this cross-sectional study of older adults participating in a local
online recruitment registry, we found that ethnoracial minorities were
less willing than their NHwhite counterparts to be contacted for stud-
ies that involved procedures typically required in AD prevention trials.
These associations were robust, independent of potential confounders
and consistent with previous reports of low participation rates among
ethnoracial minorities in AD research.4-6 Our findings underscore the
pressing need to understand the factors that could improve recruit-
ment of underrepresented older adults in research and the role that
recruitment registries may play in addressing this disparity.24,25
Recruitment registries aim to lower barriers to clinical trial enroll-
ment by increasing awareness and improving access to available trials
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TABLE 4 Association of race/ethnicity with willingness to engage in studies involving requirements of AD prevention trials
a
Odds ratios (95%CI) for higher willingness to be contacted
Unadjusted P-value Adjusted
b
P-value
Race/ethnicity
NHwhite 1.00 (ref) 1.00 (ref)
Hispanic (any race) 0.62 (0.44-0.88) .0070 0.56 (0.39-0.83) .0031
NHAsian 0.62 (0.42-0.93) .0195 0.54 (0.36-0.82) .0034
NH black 0.40 (0.19-0.81) .0117 0.36 (0.16-0.80) .0122
Age (10-year difference) 0.95 (0.86-1.05) .3237 0.98 (0.97-0.99) .0008
Sex (male vs female) 1.56 (1.27-1.91) <.0001 1.72 (1.38-2.13) <.0001
Educational attainment
High school or less (≤12 years) 0.95 (0.66-1.37) .7876 0.98 (0.65-1.48) .9266
Some college (13-15 years) 1.28 (0.98-1.66) .0655 1.29 (0.97-1.70) .0752
College or higher (≥16 years) 1.00 (ref) 1.00 (ref)
Number of comorbidities
None 1.00 (ref) 1.00 (ref)
1 1.19 (0.95-1.49) .1397 1.13 (0.88-1.47) .3345
≥2 1.35 (1.06-1.70) .0139 1.10 (0.82-1.49) .5188
Number of medications
None 1.00 (ref) 1.00 (ref)
1-2 1.31 (0.99-1.74) .0562 1.26 (0.94-1.69) .1209
3-4 1.59 (1.18-2.14) .0024 1.41 (1.00-1.97) .0475
>4 1.69 (1.26-2.26) .0005 1.46 (1.02-2.09) .0375
CFI scores (3-point difference) 1.17 (1.03-1.33) .0146 1.06 (1.02-1.14) .0062
RAQ scores (5-point difference) 1.25 (1.12-1.39) <.0001 1.05 (1.03-1.08) <.0001
Abbreviations: CFI, Cognitive Function Inventory; CI, confidence intervals; NH, non-Hispanic; RAQ, Research AttitudeQuestionnaire
aExcluded participants with neurological disorders and non-squamous cell or non-basal cell cancers.
bAdjusted for age, sex, educational attainment, number of comorbidities, number of medications, CFI and RAQ scores.
among enrollees.26 Our findings suggest that, in contrast to previous
reports,11 access alone might not be sufficient for reducing recruit-
ment disparities by race and ethnicity in AD research, particularly for
interventional trials. It is likely that greater education and engagement
will be needed to address shared barriers to participation among
diverse minority groups, which can include mistrust of researchers
and consequent fear of participation, stigma related to participation,
and competing demands involving time and financial challenges.27 For
example, a recent intervention used an educational outreach program
based upon social marketing principles and community engagement
to improve African American participation in AD studies involving LP,
PET, and MRI imaging.28 Notably, this approach required many years
of continuous effort, but ultimately yielded potentially critical discov-
eries related to disparities in AD biology.29 Other interventions have
shown promise in efforts to build trust with oldermembers of minority
communities and thereby reduce fears, particularly when researchers
do not share ethnoracial membership with targeted enrollment
groups.30 For Hispanic elders, for example, culturally appropriate
outreach materials may need to account for level of acculturation,
immigration status and history, family values, health beliefs, and level
of health literacy.31 Indeed, future efforts to improve recruitment of
multicultural populations in AD trials will likely need to use a range
of approaches to community engagement that is tailored to each
ethnoracial group.
While research attitudes—as measured by the RAQ—were an inde-
pendent predictor of AD trial participation, consistent with previous
studies,32,33 RAQ score did not appear to mediate ethnoracial minori-
ties’ lower willingness to participate. Thus, educational and engage-
ment interventions targeting attitudes beyond those measured by the
RAQ may be necessary to fully address disparities in participation. In
particular, future research should aim to gain better insights into the
role of ethnicity and culture in shaping attitudes about participation in
AD trials. For example, cultural stigma associated with a diagnosis of
dementia may pose a critical barrier for participation among Chinese
American elders34 andMexican Americans at risk for AD.35 Moreover,
cross-sectional studies about brain donation suggest an influence of
religion and spirituality inminority groups’ research decisions.36-39 For
African Americans, reluctance to participatemay be exacerbated by an
acute awareness of past breaches of trust and the pervasive history
of racism in clinical research.14,38,40 More work is needed to under-
stand how cultural values and experiences shapewillingness to engage
in potentially invasive AD biomarker testing.
Surprisingly, we found that NH Asians were more willing than NH
whites to be contacted for studies involving LP. This contrasts with
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a 2-year prospective study of 352 subjects who participated in AD
research, which reported a 77% lower agreement rate for LP among
Asians compared to whites.41 Furthermore, those who viewed LP as a
“frightening, invasive procedure” were 89% less likely to subsequently
agree to the procedure than those who viewed it as a “standard med-
ical procedure.” It is likely that relatively more NH Asian participants
in this study, compared to the other ethnoracial groups, were exposed
to educational outreach activities that included education about the
LP through our ADRC as part of broader recruitment efforts of older
Chinese adults. To corroborate this, we observed that a higher propor-
tion of NH Asians compared to other groups enrolled in C2C through
community events like public seminars. Future research will explore
whether C2C participants who express a willingness to be contacted
for studies involving LP actually participate.
We note several limitations in the present study. First, the cross-
sectional design does not allow us to infer a causal relationship
between research attitudes and researchwillingness. For instance, it is
possible that previous negative experiences with medical procedures
may have shaped negative attitudes toward research. It is also possi-
ble that the differential source of enrollment among NH Asian partici-
pants introduced selection bias. Our ethnoracial categorizations were
defined broadly, encompassing a wide range of countries of origin,
diverse cultures, religious affiliations, and immigration statuses within
eachgroup, particularly for thoseofHispanic origin andNHAsianback-
grounds. Nonetheless, these ethnoracial classifications were based on
self-report, as is typically done in clinical trials. In addition, the edu-
cational attainment of our sample was higher than that reported at
the national level,42 thus supporting previous literature about the per-
sistence of a “digital divide” by socioeconomic status among older
adults.43 For these reasons, our ability to generalize the findings is lim-
ited. How these results compare to other local registries, as well as
larger national registries, should be the focus of future research.
In summary, we found that ethnoracial minorities were less will-
ing to engage in some research studies than NH whites. We found no
evidence to support mediation by research attitudes measured by the
RAQ. Future work will focus on following these participants longitudi-
nally to assess whether those who indicated willingness actually enroll
in studies, including AD prevention trials.
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